Morgan Stanley raised the firm’s price target on iRhythm (IRTC) to $160 from $130 and keeps an Overweight rating on the shares. The firm says a a quick look at iRhythm’s Q2 app downloads points to upside risk versus Street estimates. The majority of Zio patches driving the company’s Q2 revenue have already been prescribed, providing a good read of the quarter, the analyst tells investors in a research note. Downloads of the MyZio app in Q2 totaled 171,169, up 74% years-over-year and up 36% versus Q1, Morgan Stanley notes. It continues to believe iRhythm is an attractive asset to own both nearer and longer term.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- Positive Outlook for iRhythm Technologies Driven by Strategic Partnerships and Consistent Growth
- Irhythm Technologies: Strong Market Position and Growth Potential Justify Buy Rating
- iRhythm Technologies Holds 2025 Annual Stockholders Meeting
- iRhythm price target raised to $167 from $130 at Citi
- iRhythm price target raised to $146 from $120 at Truist